Syntax Advisors, LLC Nektar Therapeutics Transaction History

Syntax Advisors, LLC

  • $57.7 Million
  • Q3 2023

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
BUY
$0.64 - $3.15 $9,162 - $45,095
14,316 Added 121.83%
26,067 $18,000
Q4 2022

Feb 14, 2023
BUY
$2.03 - $4.28 $23,854 - $50,294
11,751 New
11,751 $26,000
Q2 2022

Aug 12, 2022
BUY
$3.17 - $6.17 $33,833 - $65,852
10,673 New
10,673 $41,000

Others Institutions Holding NKTR

# of Institutions
153
Shares Held
131M
Call Options Held
92.7K
Put Options Held
4.9K
View Full List

About NEKTAR THERAPEUTICS

NKTR Quotes by TradingView
  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $163M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Syntax Advisors, LLC Portfolio

Follow Syntax Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Syntax Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Syntax Advisors, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email